Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 792 entries
Sorted by: Best Match Show Resources per page
Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals.

ClinicoEconomics and outcomes research : CEOR

Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT.
PMID: 28860831
Clinicoecon Outcomes Res. 2017 Aug 16;9:495-503. doi: 10.2147/CEOR.S140866. eCollection 2017.

OBJECTIVE: With the introduction of new therapies, hospitals have to plan spending limited resources in a cost-effective manner. To assist in identifying the optimal treatment for patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, budget impact modeling was...

Cite
Ortendahl JD, Pulgar SJ, Mirakhur B, et al. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res. 2017;9:495-503doi: 10.2147/CEOR.S140866.
Ortendahl, J. D., Pulgar, S. J., Mirakhur, B., Cox, D., Bentley, T. G., & Phan, A. T. (2017). Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. ClinicoEconomics and outcomes research : CEOR, 9495-503. https://doi.org/10.2147/CEOR.S140866
Ortendahl, Jesse D, et al. "Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals." ClinicoEconomics and outcomes research : CEOR vol. 9 (2017): 495-503. doi: https://doi.org/10.2147/CEOR.S140866
Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res. 2017 Aug 16;9:495-503. doi: 10.2147/CEOR.S140866. eCollection 2017. PMID: 28860831; PMCID: PMC5566387.
Copy Download .nbib Format: NLM
Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors.

OncoTargets and therapy

Kotteas EA, Syrigos KN, Saif MW.
PMID: 26929640
Onco Targets Ther. 2016 Feb 09;9:699-704. doi: 10.2147/OTT.S72155. eCollection 2016.

Neuroendocrine tumors are a rare and heterogeneous group of tumors with a variety of primary origins and variable aggressiveness. Platinum-based chemotherapy has been the cornerstone of treatment for the poorly differentiated tumors. However, well-differentiated neuroendocrine tumors are quite chemoresistant...

Cite
Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther. 2016;9:699-704doi: 10.2147/OTT.S72155.
Kotteas, E. A., Syrigos, K. N., & Saif, M. W. (2016). Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. OncoTargets and therapy, 9699-704. https://doi.org/10.2147/OTT.S72155
Kotteas, Elias A, et al. "Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors." OncoTargets and therapy vol. 9 (2016): 699-704. doi: https://doi.org/10.2147/OTT.S72155
Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther. 2016 Feb 09;9:699-704. doi: 10.2147/OTT.S72155. eCollection 2016. PMID: 26929640; PMCID: PMC4755420.
Copy Download .nbib Format: NLM
Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review.

Oncology letters

Zavras N, Schizas D, Machairas N, Damaskou V, Economopoulos N, Machairas A.
PMID: 28454406
Oncol Lett. 2017 Apr;13(4):2373-2376. doi: 10.3892/ol.2017.5678. Epub 2017 Feb 06.

A carcinoid tumor of the pancreas (CTP) is a rare pancreatic neoplasm, and usually presents with carcinoid syndrome (CS). CS consists of the classic symptom triad of cutaneous flushing, diarrhea and valvular disease, and occurs in the majority of...

Cite
Zavras N, Schizas D, Machairas N, et al. Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review. Oncol Lett. 2017;13(4):2373-2376doi: 10.3892/ol.2017.5678.
Zavras, N., Schizas, D., Machairas, N., Damaskou, V., Economopoulos, N., & Machairas, A. (2017). Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review. Oncology letters, 13(4), 2373-2376. https://doi.org/10.3892/ol.2017.5678
Zavras, Nikolaos, et al. "Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review." Oncology letters vol. 13,4 (2017): 2373-2376. doi: https://doi.org/10.3892/ol.2017.5678
Zavras N, Schizas D, Machairas N, Damaskou V, Economopoulos N, Machairas A. Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review. Oncol Lett. 2017 Apr;13(4):2373-2376. doi: 10.3892/ol.2017.5678. Epub 2017 Feb 06. PMID: 28454406; PMCID: PMC5403383.
Copy Download .nbib Format: NLM
Variceal haemorrhage: An update on treatment.

Journal of gastroenterology and hepatology

Sung JJ.
PMID: 28976657
J Gastroenterol Hepatol. 1998 Nov;13:S161-S165. doi: 10.1111/j.1440-1746.1998.tb01870.x.

Recent advances in the management of variceal haemorrhage include injection of cyanoacrylate and the use of banding ligation. New pharmacological agents, such as somatostatin and octreotide, have also proved to be effective in controlling variceal haemorrhage. The transjugular intrahepatic...

Cite
Sung JJ. Variceal haemorrhage: An update on treatment. J Gastroenterol Hepatol. 1998;13:S161-S165doi: 10.1111/j.1440-1746.1998.tb01870.x.
Sung, J. J. (1998). Variceal haemorrhage: An update on treatment. Journal of gastroenterology and hepatology, 13S161-S165. https://doi.org/10.1111/j.1440-1746.1998.tb01870.x
Sung, Joseph Jy. "Variceal haemorrhage: An update on treatment." Journal of gastroenterology and hepatology vol. 13 (1998): S161-S165. doi: https://doi.org/10.1111/j.1440-1746.1998.tb01870.x
Sung JJ. Variceal haemorrhage: An update on treatment. J Gastroenterol Hepatol. 1998 Nov;13:S161-S165. doi: 10.1111/j.1440-1746.1998.tb01870.x. PMID: 28976657.
Copy Download .nbib Format: NLM
Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump.

Case reports in medicine

Khan M, Ouyang J, Perkins K, Somauroo J, Joseph F.
PMID: 26089909
Case Rep Med. 2015;2015:545029. doi: 10.1155/2015/545029. Epub 2015 May 19.

Postural Tachycardia Syndrome (PoTS) represents a disorder of the autonomic nervous system that results in symptoms of orthostatic intolerance. Despite having a severe impact on the patient's quality of life, the current treatment options for PoTS are based on...

Cite
Khan M, Ouyang J, Perkins K, et al. Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump. Case Rep Med. 2015;2015:545029doi: 10.1155/2015/545029.
Khan, M., Ouyang, J., Perkins, K., Somauroo, J., & Joseph, F. (2015). Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump. Case reports in medicine, 2015545029. https://doi.org/10.1155/2015/545029
Khan, Muhammad, et al. "Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump." Case reports in medicine vol. 2015 (2015): 545029. doi: https://doi.org/10.1155/2015/545029
Khan M, Ouyang J, Perkins K, Somauroo J, Joseph F. Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump. Case Rep Med. 2015;2015:545029. doi: 10.1155/2015/545029. Epub 2015 May 19. PMID: 26089909; PMCID: PMC4452321.
Copy Download .nbib Format: NLM
Peripheral Bronchial Carcinoid Tumor Presenting as a Right Cardiophrenic Angle Mass.

Radiology case reports

Eleid MF, Hsu PY, Appleton CP, Collins JM.
PMID: 27303475
Radiol Case Rep. 2015 Dec 07;2(3):80. doi: 10.2484/rcr.v2i3.80. eCollection 2007.

A 50-year-old woman presented for evaluation of an enlarging right cardiophrenic angle mass. Two years prior she complained of intermittent nausea, diarrhea, and flushing. Initial chest radiography and computed tomography (CT) suggested a pericardial cyst. Due to the onset...

Cite
Eleid MF, Hsu PY, Appleton CP, et al. Peripheral Bronchial Carcinoid Tumor Presenting as a Right Cardiophrenic Angle Mass. Radiol Case Rep. 2015;2(3):80doi: 10.2484/rcr.v2i3.80.
Eleid, M. F., Hsu, P. Y., Appleton, C. P., & Collins, J. M. (2007). Peripheral Bronchial Carcinoid Tumor Presenting as a Right Cardiophrenic Angle Mass. Radiology case reports, 2(3), 80. https://doi.org/10.2484/rcr.v2i3.80
Eleid, Mackram F, et al. "Peripheral Bronchial Carcinoid Tumor Presenting as a Right Cardiophrenic Angle Mass." Radiology case reports vol. 2,3 (2007): 80. doi: https://doi.org/10.2484/rcr.v2i3.80
Eleid MF, Hsu PY, Appleton CP, Collins JM. Peripheral Bronchial Carcinoid Tumor Presenting as a Right Cardiophrenic Angle Mass. Radiol Case Rep. 2015 Dec 07;2(3):80. doi: 10.2484/rcr.v2i3.80. eCollection 2007. PMID: 27303475; PMCID: PMC4895065.
Copy Download .nbib Format: NLM
Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept.

Minerva chirurgica

VAN DEN Heuvel B, Peeters M, Hendlisz A, VAN DEN Eynde M, Machiels G, Dero I, Geboes K, DE Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraten E, VAN Laethem JL, Lybaert W, Holbrechts S, Rolfo C.
PMID: 26771252
Minerva Chir. 2016 Jan 15; Epub 2016 Jan 15.

BACKGROUND: The aim of this study is to investigate the role of Octreotide LAR in secondary prevention in patients with chemotherapy-induced diarrhea.METHODS: In this study, patients experiencing CID ≥ grade 2 received 30 mg long-acting octreotide as a monthly...

Cite
VAN DEN Heuvel B, Peeters M, Hendlisz A, et al. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva Chir. 2016;
VAN DEN Heuvel, B., Peeters, M., Hendlisz, A., VAN DEN Eynde, M., Machiels, G., Dero, I., Geboes, K., DE Man, M., Hendrickx, K., Delaunoit, T., Monsaert, E., Vanderstraten, E., VAN Laethem, J. L., Lybaert, W., Holbrechts, S., & Rolfo, C. (2016). Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva chirurgica, .
VAN DEN Heuvel, Bert, et al. "Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept." Minerva chirurgica vol. (2016).
VAN DEN Heuvel B, Peeters M, Hendlisz A, VAN DEN Eynde M, Machiels G, Dero I, Geboes K, DE Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraten E, VAN Laethem JL, Lybaert W, Holbrechts S, Rolfo C. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva Chir. 2016 Jan 15; Epub 2016 Jan 15. PMID: 26771252.
Copy Download .nbib Format: NLM
Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide.

Frontiers in medicine

Patel S, Nguyen DS, Rastogi A, Nguyen MK, Nguyen MK.
PMID: 28352627
Front Med (Lausanne). 2017 Mar 14;4:17. doi: 10.3389/fmed.2017.00017. eCollection 2017.

BACKGROUND: Hyponatremia in the setting of cirrhosis is a common electrolyte disorder with few therapeutic options. The free water retention is due to non-osmotic vasopressin secretion resulting from the cirrhosis-associated splanchnic vasodilatation. Therefore, vasoconstrictive therapy may correct this electrolyte...

Cite
Patel S, Nguyen DS, Rastogi A, et al. Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide. Front Med (Lausanne). 2017;4:17doi: 10.3389/fmed.2017.00017.
Patel, S., Nguyen, D. S., Rastogi, A., Nguyen, M. K., & Nguyen, M. K. (2017). Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide. Frontiers in medicine, 417. https://doi.org/10.3389/fmed.2017.00017
Patel, Sharad, et al. "Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide." Frontiers in medicine vol. 4 (2017): 17. doi: https://doi.org/10.3389/fmed.2017.00017
Patel S, Nguyen DS, Rastogi A, Nguyen MK, Nguyen MK. Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide. Front Med (Lausanne). 2017 Mar 14;4:17. doi: 10.3389/fmed.2017.00017. eCollection 2017. PMID: 28352627; PMCID: PMC5348528.
Copy Download .nbib Format: NLM
Nutritional support in patients with gastrointestinal fistula.

European journal of trauma and emergency surgery : official publication of the European Trauma Society

Yanar F, Yanar H.
PMID: 26815104
Eur J Trauma Emerg Surg. 2011 Jun;37(3):227. doi: 10.1007/s00068-011-0105-6. Epub 2011 Apr 19.

Gastrointestinal fistulas (GIFs) arise as a complication of the surgical treatment of a number of malignant and non-malignant diseases. Fluid loss and electrolyte and nutritional imbalance are related to increased morbidity and mortality in these patients. A multidisciplinary approach...

Cite
Yanar F, Yanar H. Nutritional support in patients with gastrointestinal fistula. Eur J Trauma Emerg Surg. 2011;37(3):227doi: 10.1007/s00068-011-0105-6.
Yanar, F., & Yanar, H. (2011). Nutritional support in patients with gastrointestinal fistula. European journal of trauma and emergency surgery : official publication of the European Trauma Society, 37(3), 227. https://doi.org/10.1007/s00068-011-0105-6
Yanar, F, and Yanar, H. "Nutritional support in patients with gastrointestinal fistula." European journal of trauma and emergency surgery : official publication of the European Trauma Society vol. 37,3 (2011): 227. doi: https://doi.org/10.1007/s00068-011-0105-6
Yanar F, Yanar H. Nutritional support in patients with gastrointestinal fistula. Eur J Trauma Emerg Surg. 2011 Jun;37(3):227. doi: 10.1007/s00068-011-0105-6. Epub 2011 Apr 19. PMID: 26815104.
Copy Download .nbib Format: NLM
GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass.

Endocrinology, diabetes & metabolism case reports

Guimarães M, Rodrigues P, Pereira SS, Nora M, Gonçalves G, Albrechtsen NW, Hartmann B, Holst JJ, Monteiro MP.
PMID: 26266036
Endocrinol Diabetes Metab Case Rep. 2015;2015:150049. doi: 10.1530/EDM-15-0049. Epub 2015 Jul 15.

UNLABELLED: Post-prandial hypoglycemia is frequently found after bariatric surgery. Although rare, pancreatic neuroendocrine tumors (pNET), which occasionally are mixed hormone secreting, can lead to atypical clinical manifestations, including reactive hypoglycemia. Two years after gastric bypass surgery for the treatment...

Cite
Guimarães M, Rodrigues P, Pereira SS, et al. GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinol Diabetes Metab Case Rep. 2015;2015:150049doi: 10.1530/EDM-15-0049.
Guimarães, M., Rodrigues, P., Pereira, S. S., Nora, M., Gonçalves, G., Albrechtsen, N. W., Hartmann, B., Holst, J. J., & Monteiro, M. P. (2015). GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinology, diabetes & metabolism case reports, 2015150049. https://doi.org/10.1530/EDM-15-0049
Guimarães, Marta, et al. "GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass." Endocrinology, diabetes & metabolism case reports vol. 2015 (2015): 150049. doi: https://doi.org/10.1530/EDM-15-0049
Guimarães M, Rodrigues P, Pereira SS, Nora M, Gonçalves G, Albrechtsen NW, Hartmann B, Holst JJ, Monteiro MP. GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinol Diabetes Metab Case Rep. 2015;2015:150049. doi: 10.1530/EDM-15-0049. Epub 2015 Jul 15. PMID: 26266036; PMCID: PMC4530374.
Copy Download .nbib Format: NLM
Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment.

Journal of clinical and translational hepatology

Bhardwaj R, Vaziri H, Gautam A, Ballesteros E, Karimeddini D, Wu GY.
PMID: 29577037
J Clin Transl Hepatol. 2018 Mar 28;6(1):105-113. doi: 10.14218/JCTH.2017.00035. Epub 2017 Dec 04.

Chylous ascites (CA) is a rare form of ascites that results from the leakage of lipid-rich lymph into the peritoneal cavity. This usually occurs due to trauma and rupture of the lymphatics or increased peritoneal lymphatic pressure secondary to...

Cite
Bhardwaj R, Vaziri H, Gautam A, et al. Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment. J Clin Transl Hepatol. 2017;6(1):105-113doi: 10.14218/JCTH.2017.00035.
Bhardwaj, R., Vaziri, H., Gautam, A., Ballesteros, E., Karimeddini, D., & Wu, G. Y. (2018). Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment. Journal of clinical and translational hepatology, 6(1), 105-113. https://doi.org/10.14218/JCTH.2017.00035
Bhardwaj, Richa, et al. "Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment." Journal of clinical and translational hepatology vol. 6,1 (2018): 105-113. doi: https://doi.org/10.14218/JCTH.2017.00035
Bhardwaj R, Vaziri H, Gautam A, Ballesteros E, Karimeddini D, Wu GY. Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment. J Clin Transl Hepatol. 2018 Mar 28;6(1):105-113. doi: 10.14218/JCTH.2017.00035. Epub 2017 Dec 04. PMID: 29577037; PMCID: PMC5863006.
Copy Download .nbib Format: NLM
Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus.

Journal of gastrointestinal oncology

DeFilippis EM, Ludwig E.
PMID: 26487953
J Gastrointest Oncol. 2015 Oct;6(5):E66-9. doi: 10.3978/j.issn.2078-6891.2015.042.

Reactivation of hepatitis B viral infection (HBVr) is a known risk in cancer patients with a history of chronic hepatitis B infection receiving cytotoxic or immunosuppressive therapies. Patients with hematologic malignancies or those who have received stem cell transplantation...

Cite
DeFilippis EM, Ludwig E. Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus. J Gastrointest Oncol. 2015;6(5):E66-9doi: 10.3978/j.issn.2078-6891.2015.042.
DeFilippis, E. M., & Ludwig, E. (2015). Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus. Journal of gastrointestinal oncology, 6(5), E66-9. https://doi.org/10.3978/j.issn.2078-6891.2015.042
DeFilippis, Ersilia M, and Ludwig, Emmy. "Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus." Journal of gastrointestinal oncology vol. 6,5 (2015): E66-9. doi: https://doi.org/10.3978/j.issn.2078-6891.2015.042
DeFilippis EM, Ludwig E. Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus. J Gastrointest Oncol. 2015 Oct;6(5):E66-9. doi: 10.3978/j.issn.2078-6891.2015.042. PMID: 26487953; PMCID: PMC4570918.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 792 entries